Fig. 3

Comparison of genomic alterations between male and female breast cancer cohorts by subtype and genes with differences in alteration frequency by cohort. a Comparison of genomic alterations between male (on the right) and female (on the left) breast cancer cohort of estrogen receptor (ER)-positive/human epidermal growth factor receptor (HER2)-negative subtypes. Asterisks reflect adjusted p < 0.05. Frequencies of alterations for MaBC and FBC include: GATA3: 26.2% vs. 15.9%; BRCA2: 13.8% vs. 5.4%; MDM2: 13.3% vs. 6.1%; TP53: 11.0% vs. 42.7%; respectively. b Comparison of genomic alterations between male (on the right) and female (on the left) breast cancer cohorts of ER-positive/HER2-positive subtypes. Asterisks reflect adjusted p < 0.05. Frequencies of alterations for MaBC and FBC include: GATA3: 36.4% versus 6.2%; MDM2: 36.4% versus 4.9%; TP53: 9.1% versus 61.7%; respectively. c Comparison of genomic alterations between male (on the right) and female (on the left) breast cancer cohorts of Triple-Negative Breast Cancer (TNBC) subtypes. Asterisk reflects adjusted p < 0.05. Frequencies of alterations for MaBC and FBC include: TP53: 25.0% versus 84.4%; respectively. d Genes with differences in alteration frequency in male and female breast cancer. Y-axis depicts the significance (negative of the log10 transformed p-value) and X-axis depicts the log2 transformed odds ratio. The dotted line on the x-axis demarcates depletion versus enrichment, where values < 0 indicate depletion and values > 0 indicate enrichment. Red text = False Discovery Rate (FDR) < 0.05, black text = p < 0.05, but FDR >  = 0.05. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2